Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies

Siyu Su; Anhua Lei; Xudong Wang; Hengxing Lu; Shuhang Wang; Yuqi Yang; Ning Li; Yi Zhang; Jin Zhang

doi:10.3390/cells11101652

Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies

Cells. 2022 May 16;11(10):1652. doi: 10.3390/cells11101652.

Authors

Siyu Su^{1

2}, Anhua Lei^{2

3

4}, Xudong Wang^{2

3

4}, Hengxing Lu², Shuhang Wang⁵, Yuqi Yang⁶, Ning Li⁵, Yi Zhang¹, Jin Zhang^{2

3

4}

Affiliations

¹ Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, China.
² Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou 311121, China.
³ Center for Stem Cell and Regenerative Medicine, Department of Basic Medical Sciences, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
⁴ Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
⁵ National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan, Beijing 100021, China.
⁶ NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, No. 83 Zhongshan Road, Guiyang 550000, China.

Abstract

The Chimeric antigen receptor (CAR)-T cell therapy has made inroads in treating hematological malignancies. Nonetheless, there are still multiple hurdles in CAR-T cell therapy for solid tumors. Primary CAR-expressing macrophage cells (CAR-Ms) and induced pluripotent stem cells (iPSCs)-derived CAR-expressing macrophage cells (CAR-iMacs) have emerged as attractive alternatives in our quest for an efficient and inexpensive approach for tumor immune cell therapy. In this review, we list the current state of development of human CAR-macrophages and provide an overview of the crucial functions of human CAR-macrophages in the field of tumor immune cell therapy.

Keywords: anticancer cell functions; chimeric antigen receptor (CAR); human primary macrophage cells; induced pluripotent stem cells (iPSC)-derived macrophage cells (iMac).

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Macrophages / metabolism
Neoplasms* / pathology
Receptors, Antigen, T-Cell / metabolism
Receptors, Chimeric Antigen* / metabolism
T-Lymphocytes

Substances

Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen

Grants and funding

The corresponding author Jin Zhang is supported by the Natural Science Foundation projects of China (91857116, 31871453), the National Key Research and Development Program of China (2018YFA0107100, 2018YFA0107103, 2018YFC1005002), the Zhejiang Innovation Team grant (2019R01004) and the Zhejiang Natural Science Foundation projects of China (LR19C120001). Besides, the co-author Anhua Lei is supported by Zhejiang Natural Science Foundation of China (LQ22H160001) and China Postdoctoral Science Foundation (2019M662035).